奥氮平与利培酮治疗精神分裂症阴性症状的对照研究

目的：探讨奥氮平与利培酮对精神分裂症阴性症状的疗效和安全性。方法：分别使用奥氮平与利培酮对86例以阴性症状为主精神分裂症患者治疗12周，用阳性与阴性症状量表（PANSS）、不良反应量表（TESS）评定疗效和安全性。结果：12周末两组PANSS总分及各因子分与治疗前比较有统计学差异（P〈0．05或P〈0．01）。8、12周末两组间比较PANSS总分及阴性因子分有统计学差异（P〈0．05或P〈0．01），TESS评分有统计学差异（P〉0．05）。结论：奥氮平治疗精神分裂症阴性症状疗效较好，且安全性高。

Control Study of Olanzapine and Risperidone on Negative Symptoms of Schizophrenia

Objective： To study the efficacy and safety of Olanzapine on negative symptoms of schizophrenia. Method： Eighty-six cases of schizophrenics with prominent negative symptoms were randomly divided into study group（ n =43 ） and control group（ n =43） . Forty-three cases of olanzapine treated patients were compared with 43 cases of risperidone treated patients. The duration of study was 12 weeks . The therapeutic efficacy and safety were assessed with the PANSS and TESS respectively. Result： After treatment ,the total scores of PANSS and TESS were statistical differences between two groups （ P 〈 0.05 or P 〈 0.01 ） respectively, especially the total scores of PANSS were significantly differences after 8 or 12 weeks of study between two groups （P 〈 0.05 or P 〈 0. 01 ） ,but the total scores of TESS had no statistical differences （ P 〉 0.05 ）. Conclusion： Olanzapine has an excellent clinical efficacy and safety in the treatment of schizophrenics with prominent negative symptoms.